Benzinga | Sep 23, 2020 07:06AM EDT

Freeline Announces Supply Agreement With Thermo Fisher Scientific For Haemophilia B Program

LONDON, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (NASDAQ:FRLN) (the "Company" or "Freeline"), a clinical stage, fully-integrated, next generation, systemic, AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases, today announces their supply agreement with Thermo Fisher Scientific Inc. ("Thermo Fisher").

This agreement secures dedicated production capacity and resources for Freeline from 2021 to 2027, inclusive. This will provide capacity for the planned Phase 2b/3 pivotal clinical trial and potential commercialisation of Freeline's haemophilia B program, FLT180a, using the Company's proprietary manufacturing platform and processes.Freeline has established the manufacturing process for FLT180a at Thermo Fisher's Cambridge facility over the past two years, most recently initiating clinical supply production there for its planned Phase 2b/3 pivotal clinical trial of FLT180a."I am delighted to announce this very significant extension of our partnership with Thermo Fisher," said Jan Thirkettle, Chief Development Officer at Freeline. "The investment in, and commitment to, Thermo Fisher's viral vector services operation gives us great confidence that they are the right partner to enable us to commercialise our haemophilia B therapy, if approved.""As demand for new gene therapies continues to grow, we have made strategic investments to expand our viral vector commercial manufacturing capabilities so we can provide our customers with an uninterrupted pathway from development to commercialisation. A great example of this is the work we are doing with Freeline to support its program to develop a novel treatment for haemophilia B and we are pleased to partner with them on this," said Chris Murphy, vice president and general manager for Thermo Fisher's viral vector services business.